Literature DB >> 19666471

Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.

Erik J Bonten1, Yvan Campos, Viateslav Zaitsev, Amanda Nourse, Brett Waddell, William Lewis, Garry Taylor, Alessandra d'Azzo.   

Abstract

Lysosomal neuraminidase-1 (NEU1) forms a multienzyme complex with beta-galactosidase and protective protein/cathepsin A (PPCA). Because of its association with PPCA, which acts as a molecular chaperone, NEU1 is transported to the lysosomal compartment, catalytically activated, and stabilized. However, the mode(s) of association between these two proteins both en route to the lysosome and in the multienzyme complex has remained elusive. Here, we have analyzed the hydrodynamic properties of PPCA, NEU1, and a complex of the two proteins and identified multiple binding sites on both proteins. One of these sites on NEU1 that is involved in binding to PPCA can also bind to other NEU1 molecules, albeit with lower affinity. Therefore, in the absence of PPCA, as in the lysosomal storage disease galactosialidosis, NEU1 self-associates into chain-like oligomers. Binding of PPCA can reverse self-association of NEU1 by causing the disassembly of NEU1-oligomers and the formation of a PPCA-NEU1 heterodimeric complex. The identification of binding sites between the two proteins allowed us to create innovative structural models of the NEU1 oligomer and the PPCA-NEU1 heterodimeric complex. The proposed mechanism of interaction between NEU1 and its accessory protein PPCA provides a rationale for the secondary deficiency of NEU1 in galactosialidosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666471      PMCID: PMC2788892          DOI: 10.1074/jbc.M109.031419

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

Review 1.  Comparative protein structure modeling of genes and genomes.

Authors:  M A Martí-Renom; A C Stuart; A Fiser; R Sánchez; F Melo; A Sali
Journal:  Annu Rev Biophys Biomol Struct       Date:  2000

2.  Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems.

Authors:  Peter Schuck; Matthew A Perugini; Noreen R Gonzales; Geoffrey J Howlett; Dieter Schubert
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

3.  Linear programming optimization and a double statistical filter for protein threading protocols.

Authors:  J Meller; R Elber
Journal:  Proteins       Date:  2001-11-15

4.  Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations.

Authors:  Jeffrey J Gray; Stewart Moughon; Chu Wang; Ora Schueler-Furman; Brian Kuhlman; Carol A Rohl; David Baker
Journal:  J Mol Biol       Date:  2003-08-01       Impact factor: 5.469

5.  Protein structure modeling with MODELLER.

Authors:  Narayanan Eswar; David Eramian; Ben Webb; Min-Yi Shen; Andrej Sali
Journal:  Methods Mol Biol       Date:  2008

6.  Processing of lysosomal beta-galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme.

Authors:  A van der Spoel; E Bonten; A d'Azzo
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

7.  Lysosomal neuraminidase. Catalytic activation in insect cells is controlled by the protective protein/cathepsin A.

Authors:  E J Bonten; A d'Azzo
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

8.  Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.

Authors:  P Schuck
Journal:  Biophys J       Date:  2000-03       Impact factor: 4.033

9.  Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice.

Authors:  Natalie de Geest; Erik Bonten; Linda Mann; Jean de Sousa-Hitzler; Christopher Hahn; Alessandra d'Azzo
Journal:  Hum Mol Genet       Date:  2002-06-01       Impact factor: 6.150

10.  Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.

Authors:  Dongning Wang; Slava Zaitsev; Garry Taylor; Alessandra d'Azzo; Erik Bonten
Journal:  Biochim Biophys Acta       Date:  2009-04
View more
  29 in total

1.  Neuraminidase-1 mediates skeletal muscle regeneration.

Authors:  Juliana de Carvalho Neves; Vanessa Rodrigues Rizzato; Alan Fappi; Mariana Miranda Garcia; Gerson Chadi; Diantha van de Vlekkert; Alessandra d'Azzo; Edmar Zanoteli
Journal:  Biochim Biophys Acta       Date:  2015-05-19

Review 2.  Lysosomal multienzyme complex: pros and cons of working together.

Authors:  Erik J Bonten; Ida Annunziata; Alessandra d'Azzo
Journal:  Cell Mol Life Sci       Date:  2013-12-15       Impact factor: 9.261

3.  Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.

Authors:  Trisha M Finlay; Preethi Jayanth; Schammim Ray Amith; Alanna Gilmour; Christina Guzzo; Katrina Gee; Rudi Beyaert; Myron R Szewczuk
Journal:  Glycoconj J       Date:  2010-03-06       Impact factor: 2.916

Review 4.  Where catabolism meets signalling: neuraminidase 1 as a modulator of cell receptors.

Authors:  Alexey V Pshezhetsky; Aleksander Hinek
Journal:  Glycoconj J       Date:  2011-09-20       Impact factor: 2.916

5.  Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency

Authors:  Amanda R Luu; Cara Wong; Vishal Agrawal; Nathan Wise; Britta Handyside; Melanie J Lo; Glenn Pacheco; Jessica B Felix; Alexander Giaramita; Alessandra d'Azzo; Jon Vincelette; Sherry Bullens; Stuart Bunting; Terri M Christianson; Charles M Hague; Jonathan H LeBowitz; Gouri Yogalingam
Journal:  J Biol Chem       Date:  2020-07-28       Impact factor: 5.157

6.  Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease.

Authors:  Alessandra d'Azzo; Erik Bonten
Journal:  Biochem Soc Trans       Date:  2010-12       Impact factor: 5.407

7.  Neuraminidase activity mediates IL-6 production by activated lupus-prone mesangial cells.

Authors:  Kamala Sundararaj; Jessalyn I Rodgers; Subathra Marimuthu; Leah J Siskind; Evelyn Bruner; Tamara K Nowling
Journal:  Am J Physiol Renal Physiol       Date:  2017-12-20

8.  NEU1 sialidase regulates the sialylation state of CD31 and disrupts CD31-driven capillary-like tube formation in human lung microvascular endothelia.

Authors:  Chunsik Lee; Anguo Liu; Alba Miranda-Ribera; Sang Won Hyun; Erik P Lillehoj; Alan S Cross; Antonino Passaniti; P Richard Grimm; Bo-Young Kim; Paul A Welling; Joseph A Madri; Horace M DeLisser; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

9.  Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.

Authors:  Erik J Bonten; Gouri Yogalingam; Huimin Hu; Elida Gomero; Diantha van de Vlekkert; Alessandra d'Azzo
Journal:  Biochim Biophys Acta       Date:  2013-06-12

10.  Galactosialidosis: historic aspects and overview of investigated and emerging treatment options.

Authors:  Ida Annunziata; Alessandra d'Azzo
Journal:  Expert Opin Orphan Drugs       Date:  2016-12-14       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.